This website uses cookies

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy

Anderson Strathern reports record-breaking year in investment deals

Anderson Strathern reports record-breaking year in investment deals


Anderson Strathern's corporate investment team excels with £46m deals, doubling value, and expanding staff

Anderson Strathern, a leading law firm, has marked another year of unparalleled success in handling investment deals, surpassing previous records for the second consecutive year. The firm's corporate investment team, led by partner Euan Tripp, has witnessed a surge in investment activity, significantly impacting both the number and value of deals undertaken.

In the past twelve months alone, the corporate investment team has orchestrated over 30 investment deals, collectively amounting to a staggering value exceeding £46 million. This noteworthy achievement represents a notable leap from the team's management of £20 million worth of investments in 2022.

With a view to accommodating this increased workload, Anderson Strathern has bolstered its corporate investment team by recruiting two newly qualified solicitors and an associate. The team's clientele spans a diverse range, encompassing active investors such as private equity funds, high-net-worth individuals, universities, and the investment arms of major corporate entities across Scotland.

The flurry of deals orchestrated by the team has predominantly revolved around investments in burgeoning sectors such as medtech, bioscience, and green energy. Notably, the team's involvement with Almero Ventures in its £1.5 million investment into Carbon Capture Scotland stands out. This venture aims to enable the decarbonization of various industries that produce CO2 during their operations.

Furthermore, the law firm has played a pivotal role in supporting long-term client, the University of Strathclyde, in multiple investment deals. One such deal involved an investment into Microplate DX, a diagnostics company pioneering a patented test to combat antimicrobial resistance by curbing antibiotic overuse.

Expressing optimism for the future, Euan Tripp highlighted the increasing trend of substantial investments in Scottish companies. He noted the growing interest from numerous clients seeking investment opportunities, particularly in innovative startups within sectors that dominated the investment landscape in 2023.

Max Scharbert, a senior director within Anderson Strathern's corporate investment team, affirmed the resilience of their clients amidst challenging market conditions. He expressed confidence in the upsurge of new funds raised in 2023, anticipating a subsequent increase in high-quality deals throughout 2024. Scotland, according to Scharbert, remains an appealing and promising destination for investors.